(Q34660736)

3 August 2017

Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia (English)

1 reference

3 August 2017

0 references

7

1 reference

3 August 2017

3

Haya Ascher-Svanum

1 reference

3 August 2017

8

John M Kane

1 reference

3 August 2017

Bruce J Kinon

1

1 reference

3 August 2017

Lei Chen

2

1 reference

3 August 2017

Virginia L Stauffer

4

1 reference

3 August 2017

Sara Kollack-Walker

5

1 reference

3 August 2017

Wei Zhou

6

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

3 August 2017

Neuropsychopharmacology

1 reference

3 August 2017

35

1 reference

3 August 2017

2

1 reference

3 August 2017

581-590

1 reference

https://scigraph.springernature.com/pub.10.1038/npp.2009.164

3 August 2017

0 references

cites work

Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

Limitations of current therapies: why do patients switch therapies?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

A meta-analysis of the efficacy of second-generation antipsychotics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

Treatment of neuroleptic-resistant schizophrenic relapse.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

A rating scale for extrapyramidal side effects

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

The positive and negative syndrome scale (PANSS) for schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

A rating scale for drug-induced akathisia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

A New Depression Scale Designed to be Sensitive to Change

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected

7 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

Early Prediction of Antipsychotic Response in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.164

Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055392

Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study

26 October 2018

1 reference

12 December 2020

Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design

1 reference

12 December 2020

Effectiveness of switching antipsychotic medications

1 reference

12 December 2020

Early prediction of antipsychotic nonresponse among patients with schizophrenia

1 reference

12 December 2020

Identifiers

DOI

10.1038/NPP.2009.164

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference